[Possible treatments for infantile spinal atrophy]

Area of Science:

• Neurology
• Genetics
• Pharmacology

Background:

• Spinal muscular atrophy (SMA) is a genetic disorder caused by SMN1 gene deletions.
• Current research explores methods to increase SMN protein levels and activity.
• Previous treatments like neuroprotective and epigenetic drugs showed limited clinical efficacy.

Purpose of the Study:

• To review novel therapeutic strategies for spinal muscular atrophy (SMA).
• To evaluate the efficacy of emerging treatments, including gene therapy and antisense oligonucleotides.
• To highlight the importance of early intervention in SMA treatment outcomes.

Main Methods:

• Review of preclinical studies and clinical trials for SMA treatments.
• Analysis of antisense oligonucleotides (ASOs) that modify SMN2 splicing.
• Examination of gene therapy approaches using adeno-associated virus vectors.

Main Results:

• Antisense oligonucleotides (e.g., nusinersen) have demonstrated significant improvements in SMA models and clinical trials.
• Nusinersen, an ASO, is approved for SMA type 1, showing efficacy in phase 3 trials.
• Gene therapy with SMN1 via adeno-associated virus is in early-stage clinical trials (phase 1).

Conclusions:

• Early and presymptomatic treatment of SMA leads to the best outcomes.
• Antisense oligonucleotides and gene therapy represent promising avenues for SMA treatment.
• Optimal results require integrated care, including nutritional and respiratory support.